Andrew Weickhardt

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resista...

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastati...

Lu-PSMA-617 plus enzalutamide bij mCRPC: PSMAfore fase III

OS met Lu-PSMA-617 versus cabazitaxel bij mCRPC: TheraP definitieve OS

[177Lu]Lu-PSMA-617 versus cabazitaxel bij mCRPC: TheraP fase II